Search filters

List of works by Johann de Bono

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

scientific article (publication date: November 2016)

90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial?

scientific article published on 10 June 2008

A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer ⬇️

scientific article published on November 24, 2010

A decade of clinical development of PARP inhibitors in perspective

scientific article published on 01 September 2019

A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer

scientific article published on 22 March 2022

A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies.

scientific article published on January 2007

A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours

scientific article published on 12 March 2009

A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors

scientific article

A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors.

scientific article

A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors

scientific article published on 07 August 2018

A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.

scientific article published on 30 January 2013

A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer

scientific article published on 16 October 2014

A robust blood gene expression-based prognostic model for castration-resistant prostate cancer

scientific article published on 21 August 2015

A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products

scientific article published in March 2018

A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials

scientific article published on 10 October 2018

A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments

scientific article published on 5 October 2017

A study of motivations and expectations of patients seen in phase 1 oncology clinics

scientific article published on 26 September 2016

A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit: unplanned admissions as an early indicator of patient attrition.

scientific article published on 11 August 2010

Abiraterone acetate: redefining hormone treatment for advanced prostate cancer ⬇️

scientific article published on December 19, 2011

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.

scientific article published on 3 June 2017

Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer

scientific article published on 23 August 2019

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

scientific article published on 21 December 2015

Advanced Solid Tumors Treated with Cediranib: Comparison of Dynamic Contrast-enhanced MR Imaging and CT as Markers of Vascular Activity ⬇️

scientific article published on August 13, 2012

Agents that target androgen synthesis in castration-resistant prostate cancer

scientific article published on January 2013

Alternative splicing in prostate cancer

scientific article published on 01 November 2018

Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials

scientific article published on 12 December 2019

Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer

BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer.

scientific article published in January 2018

Belinostat: clinical applications in solid tumors and lymphoma ⬇️

scientific article published on November 3, 2011

Beyond Hormone Therapy for Prostate Cancer with PARP inhibitors

scientific article published on 01 May 2011

Biomarkers in early clinical trials: the committed and the skeptics

scientific article published on 01 April 2008

CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo

scientific article published on 06 April 2020

CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions

scientific article published in Nature

Cabazitaxel in Metastatic Prostate Cancer. Reply

scientific article published on 01 March 2020

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

scientific article published on 30 September 2019

Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study

scientific article

Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study

scientific article (publication date: 15 January 2003)

Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses

scientific article published on 05 May 2016

Changing Therapeutic Paradigms in Castrate-Resistant Prostate Cancer ⬇️

scientific article published on December 1, 2010

Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions.

scientific article

Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.

scientific article published on 27 April 2017

Circulating cell-free DNA: Translating prostate cancer genomics into clinical care

scientific article published on 16 January 2020

Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients

scientific article published on 10 April 2018

Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer

scientific article

Clinical benefit of early phase clinical trial participation for advanced sarcoma patients

scientific article

Clinical benefit of new targeted agents in phase I trials in patients with advanced colorectal cancer

scientific article published on 23 January 2009

Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel

scientific article published on 7 February 2017

Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial

scientific article published on 27 June 2014

Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer.

scientific article published on 15 January 2018

Consensus on molecular imaging and theranostics in prostate cancer

scientific article published on 01 December 2018

Continued targeting of androgen receptor signalling: a rational and efficacious therapeutic strategy in metastatic castration-resistant prostate cancer ⬇️

scientific article published on September 1, 2011

Corrigendum to 'Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer' [European Journal of Cancer 76 (2017) 36-44].

scientific article

Creatinine Clearance Is Associated with Toxicity from Molecularly Targeted Agents in Phase I Trials ⬇️

scientific article published on 07 August 2012

Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus

scientific article published on January 2008

DNA Repair and Prostate Cancer: A Field Ripe for Harvest

scientific article published on 04 July 2020

Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer

scientific article published on 8 June 2016

Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways ⬇️

scientific article published on March 18, 2013

Development of a molecular profiling assay for circulating tumor cells (CTCs) utilizing automated multiplexed in situ hybridization for metastatic castrate-resistant prostate cancer (mCRPC).

scientific article published in 2012

Differential impact of RB status on E2F1 reprogramming in human cancer

scientific article

Disrupting Androgen Receptor Signaling Induces Snail-Mediated Epithelial-Mesenchymal Plasticity in Prostate Cancer

scientific article published on 16 March 2017

Drugs and the exercise test ⬇️

scientific article published on October 3, 1992

Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).

scientific article published on 8 January 2007

Early Oncology Clinical Trial Design in the Era of Molecular-Targeted Agents ⬇️

scientific article published on August 1, 2010

Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy ⬇️

scientific article published on November 14, 2012

Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors

scientific article published on 9 November 2009

Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study

scientific article published on 06 August 2013

Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial

scientific article published on 27 August 2014

Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies

scientific article published in 2021

Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis

scientific article published on 06 August 2014

Enzalutamide in European and North American men participating in the AFFIRM trial

scientific article published on 23 October 2014

EpCAM and EpCAM circulating tumor cells in metastatic prostate and breast cancer patients

scientific article published on 02 November 2018

Erratum to: Methods for evaluating medical tests and biomarkers

scientific article published on 30 March 2017

Evolution of androgen receptor targeted therapy for advanced prostate cancer

scientific article published on 20 May 2014

Expression profiling of CD133+ and CD133- epithelial cells from human prostate.

scientific article

Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial

scientific article

Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma ⬇️

scientific article published on October 1, 2003

Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial

scientific article

Flexible trial design in practice – dropping and adding arms in STAMPEDE: a multi-arm multi-stage randomised controlled trial

scientific article

Future directions in the evaluation of c-MET-driven malignancies ⬇️

scientific article published on November 1, 2011

Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification

scientific article published on 27 July 2017

Genetic Analysis of Circulating Tumour Cells

scientific article published on 01 January 2020

HDAC inhibitors and cardiac safety

scientific article published on 01 February 2007

HER3 Is an Actionable Target in Advanced Prostate Cancer

scientific article published on 09 November 2021

Histone deacetylase inhibitors: emerging anticancer therapeutic agents?

scientific article

Hypoxia and Noncoding RNAs in Taxane Resistance

scientific article published on 08 June 2018

IL-23 secreted by myeloid cells drives castration-resistant prostate cancer

scientific article published in Nature

Identification of factors limiting patient recruitment into phase I trials: a study from the Royal Marsden Hospital

scientific article published on 24 March 2008

Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art

scientific article published on 25 June 2019

Immunotherapy for lethal prostate cancer

scientific article published on 01 February 2019

Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial ⬇️

scientific article published on May 30, 2013

Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms

scientific article

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

scientific article published on 06 July 2016

Integrative Clinical Genomics of Advanced Prostate Cancer

scientific article

Integrative clinical genomics of advanced prostate cancer

scientific article

Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey

scientific article published on 10 October 2016

Interview with Johann de Bono for Future Oncology. Interviewed by Francesca Lake

scientific article published in November 2012

Is there an antiandrogen withdrawal syndrome with enzalutamide?

scientific article published on 24 October 2014

JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer

scientific article published on 01 February 2021

Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action

scientific article published on October 2016

MDV3100 for the treatment of prostate cancer ⬇️

scientific article published on January 10, 2012

METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer.

scientific article

Making sense of antisense

scientific article published on 09 November 2005

Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019

scientific article published on 27 January 2020

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

scientific article

Management of patients with castration-resistant disease.

scientific article published on 20 September 2013

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

scientific article

Metabolomic changes of the multi (-AGC-) kinase inhibitor AT13148 in cells, mice and patients are associated with NOS regulation

scientific article published on 13 April 2020

Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics

scientific article published on September 2014

Methods for Evaluating Medical Tests and Biomarkers

article by Gowri Gopalakrishna et al published February 2017 in Diagnostic and Prognostic Research

Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab

scientific article published on 01 March 2020

Neutrophil to Lymphocyte Ratio in Castration-Resistant Prostate Cancer Patients Treated With Daily Oral Corticosteroids.

scientific article published on 10 May 2017

Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors.

scientific article published on 8 December 2017

New therapies for castration-resistant prostate cancer: efficacy and safety

scientific article published on 04 May 2011

Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting

scientific article

Olaparib for Metastatic Castration-Resistant Prostate Cancer

scientific article published on 28 April 2020

Olaparib for Metastatic Castration-Resistant Prostate Cancer. Reply

scientific article published on 01 August 2020

Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.

scientific article

Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities

scientific article published on 19 March 2012

Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma

scientific article published on 05 October 2020

PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients

scientific article

PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.

scientific article published on 4 November 2014

Parallel anticancer drug development and molecular stratification to qualify predictive biomarkers: dealing with obstacles hindering progress

scientific article published on 01 August 2011

Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer

scientific article

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.

scientific article

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study

scientific article published on 27 November 2019

Perceptions and referral trends into phase I oncology trials: results of a clinical survey

scientific article

Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer

scientific article published on 21 May 2019

Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers

scientific article published on 01 October 2007

Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.

scientific article

Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies

scientific article published on 01 August 2007

Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer

scientific article

Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers.

scientific article

Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors.

scientific article

Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors

scientific article published on 25 November 2014

Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?

scientific article published on 28 March 2011

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

scientific article

Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer.

scientific article

Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy ⬇️

scientific article published on September 7, 2011

Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors

scientific article published on 2 October 2013

Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m(2)) and the Currently Approved Dose (25 mg/m(2)) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.

scientific article

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.

scientific article

Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based th

scientific article published on 26 January 2015

Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer

scientific article

Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression

scientific article published on 06 December 2018

Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic ⬇️

scientific article published on 04 January 2011

Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib.

scientific article published on 14 March 2014

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial ⬇️

scientific article (publication date: 2 October 2010)

Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration‐resistant prostate cancer ⬇️

scientific article published on January 26, 2011

Prognostic factors for survival in the phase III TROPIC trial

Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy

scientific article published on 17 October 2013

Prospective validation of a prognostic score to improve patient selection for oncology phase I trials

scientific article

Prostate cancer: evolution or revolution?

scientific article published on 22 August 2011

Prostate carcinogenesis: inflammatory storms

scientific article published on 16 June 2020

Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy

scientific article published on 07 October 2013

Publisher Correction: Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer

scientific article published on 01 September 2018

Publisher Correction: The long tail of oncogenic drivers in prostate cancer

scientific article published on 01 July 2019

Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study

scientific article published on 11 September 2020

RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease

publication published on 20 April 2021

RB1 Heterogeneity in Advanced Metastatic Castration Resistant Prostate Cancer

scientific article published on 26 September 2018

RETRACTED: Horizon scanning for novel therapeutics for the treatment of prostate cancer ⬇️

scientific article published on September 24, 2010

RNAi screen reveals synthetic lethality between cyclin G-associated kinase and FBXW7 by inducing aberrant mitoses

scientific article

Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL.

scientific article

Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer ⬇️

scientific article published on November 28, 2011

Rationale for Modernising Imaging in Advanced Prostate Cancer.

scientific article published on 15 July 2016

Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer

scientific article published on 01 August 2019

Re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olap

scientific article published on 22 December 2020

Reappraisal of glucocorticoids in castrate-resistant prostate cancer

scientific article published on September 2014

Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancer

scientific article published on 01 September 2018

Reovirus activates human dendritic cells to promote innate antitumor immunity

scientific article

Reply from authors re: Camillo Porta, Sergio Bracarda, Romano Danesi. Steroids in prostate cancer: the jury is still out... and even more confused. Eur Urol 2015;67:680-1: Corticosteroids in prostate cancer: known benefits versus potential risks

scientific article published on 29 November 2014

Reply to M. Horiguchi et al.

scientific article published on 26 January 2018

Reply to Robert J. van Soest and Ronald de Wit's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistan

scientific article

Reply to Vincenza Conteduca, Giorgia Gurioli, and Ugo De Giorgi's Letter to the Editor re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant

scientific article published on 01 June 2018

Revisiting the Role of Antiandrogen Strategies in Ovarian Cancer ⬇️

scientific article published on September 23, 2011

SOX9 is a driver of aggressive prostate cancer by promoting invasion, cell fate and cytoskeleton alterations and epithelial to mesenchymal transition

scientific article published on 10 January 2018

SPOP mutation leads to genomic instability in prostate cancer.

scientific article

SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity

scientific article published on 01 August 2018

Sarcomatoid carcinoma of the prostate: ERG fluorescence in-situ hybridization confirms epithelial origin

scientific article published on 10 November 2014

Scanning Electron Microscopy of Circulating Tumor Cells and Tumor-Derived Extracellular Vesicles

scientific article published on 31 October 2018

Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells.

scientific article published on May 2016

Second-generation antiandrogens in nonmetastatic CRPC

scientific article published on 01 June 2018

Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents

scientific article published on 16 August 2013

Secondary mutations inBRCA2associated with clinical resistance to a PARP inhibitor

article by Louise J Barber et al published 25 January 2013 in Journal of Pathology

Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets

scientific article published on 16 April 2018

Serum Androgens As Prognostic Biomarkers in Castration-Resistant Prostate Cancer: Results From an Analysis of a Randomized Phase III Trial ⬇️

scientific article published on August 1, 2013

Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial

scientific article published on 29 January 2016

Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis

scientific article published on 09 August 2018

Study protocol for a randomised controlled trial of enhanced informed consent compared to standard informed consent to improve patient understanding of early phase oncology clinical trials (CONSENT)

scientific article published on 06 September 2021

Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).

scientific article

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

scientific article published on 20 September 2020

Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in?

scientific article published on 06 April 2020

Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre

scientific article published on 15 October 2018

Targeted therapeutics for cancer treatment: major progress towards personalised molecular medicine

scientific article published on 21 August 2008

Targeting IGF-1R: throwing out the baby with the bathwater? ⬇️

scientific article published on January 4, 2011

Targeting Insulin-Like Growth Factor Signaling: Rational Combination Strategies ⬇️

scientific article published on August 31, 2010

Targeting cell cycle kinases and kinesins in anticancer drug development ⬇️

scientific article published on April 1, 2007

Targeting defective DNA repair in prostate cancer

scientific article published on 15 July 2020

Targeting polo-like kinase: learning too little too late?

scientific article published on 27 October 2008

Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies ⬇️

scientific article published on July 22, 2011

Targeting the p300/CBP Axis in Lethal Prostate Cancer

scientific article published on 11 January 2021

The 'Pushmi-Pullyu' of DNA REPAIR: Clinical Synthetic Lethality

scientific article

The Emerging Role of Poly(ADP-Ribose) Polymerase Inhibitors in Cancer Treatment ⬇️

scientific article published on December 1, 2011

The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

scientific article published on 19 March 2016

The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.

scientific article

The changing therapeutic landscape of castration-resistant prostate cancer ⬇️

scientific article published on 09 August 2011

The landscape of RNA polymerase II associated chromatin interactions in prostate cancer

scientific article published on 28 April 2020

The long tail of oncogenic drivers in prostate cancer.

scientific article published on 2 April 2018

The molecular underpinnings of prostate cancer: impacts on management and pathology practice

scientific article

The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials.

scientific article published on 31 March 2018

Therapeutic Options for Advanced Prostate Cancer: 2011 Update ⬇️

scientific article published on April 1, 2012

Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC) ⬇️

scientific article published on August 7, 2013

Toward a better dialogue between neuro-oncologists and phase I investigators.

scientific article

Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap)

scientific article published on 19 September 2018

Translating cancer research into targeted therapeutics ⬇️

scientific article published on September 30, 2010

Treatment of Advanced Prostate Cancer-A Review of Current Therapies and Future Promise

scientific article published on 3 November 2017

Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours

scientific article published on 12 March 2020

Update on tubulin-binding agents.

scientific article

c-MET: an exciting new target for anticancer therapy ⬇️

scientific article published on November 1, 2011

Paulina is supported by:

About Paulina

Help